Prostatype Genomics AB (PROGEN) Price & Analysis

PROGEN Stock Chart & Stats

SEK 0.11SEK 0.00(0.00%)

At close: Oct 30 4:00 PM EDT

Day’s Range: SEK 0.10 - SEK 0.11
52-Week Range: SEK 0.08 - SEK 0.87
Previous Close: SEK 0.11
Volume: 7,013
Average Volume (3M): 7.76M
Market Cap: SEK 74.32M
Enterprise Value: SEK 25.06M
Total Cash (Recent Filing): SEK 392.00K
Total Debt (Recent Filing): SEK 0
Price to Earnings (P/E): ―
Beta: -0.24
Next Earnings: Feb 11, 2027
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Focused Precision-medicine Business

The company operates in a focused precision-medicine niche, using genomic and biomarker analysis to support prostate-cancer treatment decisions. A specialized diagnostic offering can create durable clinical relevance if adoption expands, because risk assessment and treatment guidance are recurring healthcare needs.

Revenue Improvement

TTM revenue growth indicates that commercial activity is improving from a small base and that the product is generating increasing sales. Continued growth would provide operating leverage over time, improve market validation, and help the company progress toward a more sustainable commercial model.

Manageable Leverage

Modest debt relative to equity gives the company some balance-sheet flexibility compared with a highly leveraged business. This can reduce interest and refinancing pressure while management works to expand revenue, although ongoing losses still make capital preservation important.

Bears Say

Severe Unprofitability

Deeply negative gross, operating, and net margins show that current revenue does not cover the economics of the business. Unless pricing, delivery economics, or operating efficiency improve materially, persistent losses will constrain reinvestment and weaken the path to sustainable profitability.

Persistent Cash Burn

Materially negative operating and free cash flow means the company is consuming cash to fund ongoing operations rather than generating internal financing. Continued burn increases dependence on future funding and leaves less flexibility to develop products, commercialize tests, or absorb execution setbacks.

Limited Commercial Scale

Small, volatile revenue and the absence of a demonstrated scalable commercial inflection point indicate that the business remains early in its commercialization cycle. This makes future results sensitive to execution and means fixed costs may continue to weigh heavily until sales expand substantially.

PROGEN FAQ

What was Prostatype Genomics AB’s price range in the past 12 months?

Prostatype Genomics AB lowest stock price was kr 0.08 and its highest was kr 0.87 in the past 12 months.

What is Prostatype Genomics AB’s market cap?

Prostatype Genomics AB’s market cap is kr 74.32M.

When is Prostatype Genomics AB’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Prostatype Genomics AB’s earnings last quarter?

Prostatype Genomics AB released its earnings results on Aug 31, 2026. The company reported -kr 0.111 earnings per share for the quarter.

Is Prostatype Genomics AB overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Prostatype Genomics AB pay dividends?

Prostatype Genomics AB does not currently pay dividends.

What is Prostatype Genomics AB’s EPS estimate?

Prostatype Genomics AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Prostatype Genomics AB have?

Prostatype Genomics AB has 691,317,100 shares outstanding.

What happened to Prostatype Genomics AB’s price movement after its last earnings report?

Prostatype Genomics AB reported an EPS of -kr 0.111 in its last earnings report. Following the earnings report the stock price went down -6.711%.

Which hedge fund is a major shareholder of Prostatype Genomics AB?

Currently, no hedge funds are holding shares in SE:PROGEN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description